一项评估 CIN-102(去甲哌啶酮)在成人糖尿病性胃轻瘫中的疗效和安全性的研究
一项随机、双盲、安慰剂对照、多中心研究,以评估 CIN-102(杜潘立酮)在患有糖尿病胃轻瘫的成人受试者中的疗效和安全性
The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help reduce the symptoms associated with diabetic gastroparesis in adult patients.
The main questions it aims to answer are:
- To evaluate the efficacy of CIN-102 on symptoms of gastroparesis when given to patients with diabetic gastroparesis compared to a placebo
- To evaluate the safety and tolerability of CIN-102 when given to patients with diabetic gastroparesis compared to a placebo
Participants will go through the following schedule:
-
Screening period (1-2 visits)
-
Lead-in period (1 visit)
- Will complete a Gastric Emptying Breath Test (GEBT)
- Will complete daily diary and other Patient Reported Outcomes (PROs) as described in the protocol to assess eligibility for continued study participation
-
12-week treatment period (7 visits)
- Study drug taken twice daily by mouth
- Will complete daily diaries and other PROs as described in protocol
-
1 week follow-up (1 visit)
Researchers will compare the effects of the following treatments:
- Drug- CIN-102 Dose 15 mg or 10 mg
- Drug- Placebo
研究概览
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
Alabama
-
Dothan、Alabama、美国、36305
- Digestive Health Specialists of the Southeast
-
Foley、Alabama、美国、36535
- G & L Research, LLC
-
Huntsville、Alabama、美国、35801
- Clinical Research Associates, LLC
-
-
Arizona
-
Peoria、Arizona、美国、85381
- Phoenix Medical Research Institute, LLC
-
Phoenix、Arizona、美国、85381
- Onyx Clinical Research
-
Tucson、Arizona、美国、85715
- Del Sol Research Management, LLC
-
-
Arkansas
-
Little Rock、Arkansas、美国、72211
- Preferred Research Partners, Inc.
-
Little Rock、Arkansas、美国、72212
- Applied Research Center of Arkansas
-
North Little Rock、Arkansas、美国、72117
- Arkansas Gastroenterology - North Little Rock
-
-
California
-
Bell Gardens、California、美国、90201
- Alliance Research Institute - Bell Gardens
-
Canoga Park、California、美国、91303
- Hope Clinical Research LLC
-
Canoga Park、California、美国、91304
- Alliance Research Institute, LLC
-
Chula Vista、California、美国、91910
- GW Research Inc.
-
Chula Vista、California、美国、91910
- Erick H. Alayo Medical Corporation
-
Corona、California、美国、92879
- Kindred Medical Institute for Clinical Trials, LLC
-
Corona、California、美国、92882
- New Hope Research Development
-
Costa Mesa、California、美国、92627
- Aurora Care Clinic
-
Garden Grove、California、美国、92840
- Paragon Rx Clinical
-
Garden Grove、California、美国、92845
- Valley View Wellness and Medical Center - VVCRD
-
Lomita、California、美国、09717
- Torrance Clinical Research Institute Inc.
-
Los Angeles、California、美国、90010
- Angel City Research
-
Mission Hills、California、美国、11333
- Facey Medical Research
-
Thousand Oaks、California、美国、91360
- Millennium Clinical Trials
-
-
Florida
-
Clearwater、Florida、美国、33756
- Innovative Research of West Florida
-
Doral、Florida、美国、33126
- USA and International Research Inc.
-
Hollywood、Florida、美国、33021
- Advanced Medical Research Group
-
Inverness、Florida、美国、34452
- Nature Coast Clinical Research
-
Maitland、Florida、美国、32751
- ClinCloud LLC
-
Miami、Florida、美国、33144
- A+ Research Inc
-
Miami、Florida、美国、33183
- International Research Associates LLC - Breton
-
New Port Richey、Florida、美国、34653
- Advanced Research Institute Inc
-
Orange City、Florida、美国、32763
- Gastroenterology of Greater Orlando
-
Viera、Florida、美国、32940
- Tandem Clinical Research - Viera
-
-
Georgia
-
Athens、Georgia、美国、30607
- Summit Clinical Research, LLC
-
Decatur、Georgia、美国、30033
- Atlanta Center for Gastroenterology P.C.
-
-
Indiana
-
Evansville、Indiana、美国、47714
- Medisphere Medical Research Center
-
Fort Wayne、Indiana、美国、46804
- Lutheran Medical Group
-
-
Kansas
-
Kansas City、Kansas、美国、66160
- University of Kansas Medical Center (KUMC)
-
Overland Park、Kansas、美国、66209
- DelRicht Clinical Research - Overland Park
-
Topeka、Kansas、美国、66606
- Kansas Medical Clinic, P.A.
-
Wichita、Kansas、美国、67205
- Alliance for Multispecialty Research - Wichita West
-
-
Kentucky
-
Louisville、Kentucky、美国、40202
- University of Louisville
-
Louisville、Kentucky、美国、40205
- DelRicht Clinical Research - Louisville
-
-
Louisiana
-
Bastrop、Louisiana、美国、71201
- Delta Research Partners
-
Houma、Louisiana、美国、70363
- Tandem Clinical Research GI - Houma
-
Marrero、Louisiana、美国、70072
- Tandem Clinical Research
-
Metairie、Louisiana、美国、70006
- Tandem Clinical Research GI - Metairie
-
-
Michigan
-
Chesterfield、Michigan、美国、48047
- Clinical Research Institute of Michigan, LLC
-
Flint、Michigan、美国、48504
- Aa Mrc, Llc
-
Troy、Michigan、美国、48098
- Clinical Research Institute of Michigan, LLC - Troy
-
Wyoming、Michigan、美国、49519
- Gastroenterology Associates of Western Michigan
-
-
Missouri
-
Kansas City、Missouri、美国、64131
- Kansas City Research Institute
-
St Louis、Missouri、美国、63110
- Washington University School of Medicine
-
Weldon Spring、Missouri、美国、63304
- St. Charles Clinical Research
-
-
Montana
-
Missoula、Montana、美国、59808
- Montana Medical Research, Inc.
-
-
Nevada
-
Las Vegas、Nevada、美国、89128
- Digestive Disease Specialists
-
Las Vegas、Nevada、美国、89123
- American Institute of Medical Research
-
-
New Jersey
-
Englewood、New Jersey、美国、07631
- Allied Health Clinical Research Organization, LLC (AHCRO) - Englewood
-
Freehold、New Jersey、美国、07728
- Allied Health Clinical Research Organization, LLC (AHCRO) - Freehold
-
Jackson、New Jersey、美国、08527
- Allied Health Clinical Research Organization, LLC (AHCRO) - Jackson
-
-
New York
-
Brooklyn、New York、美国、11235
- NY Scientific
-
Brooklyn、New York、美国、11372
- Smart Medical Research
-
East Syracuse、New York、美国、13057
- Velocity Clinical Research - Syracuse
-
New York、New York、美国、10033
- Tandem Clinical Research GI- New York
-
Richmond Hill、New York、美国、11418
- A1 Clinical Network
-
-
North Carolina
-
Charlotte、North Carolina、美国、28144
- OnSite Clinical Solutions, LLC
-
Charlotte、North Carolina、美国、28204
- Atrium Health - Center for Digestive Health
-
Denver、North Carolina、美国、28037
- Research Carolina Elite, LLC
-
Fayetteville、North Carolina、美国、28304
- Coastal Research Institute, LLC
-
Fayetteville、North Carolina、美国、28304
- Cross Creek Medical, PA
-
Greensboro、North Carolina、美国、27410
- Triad Clinical Trials LLC
-
High Point、North Carolina、美国、27260
- Peters Medical Research
-
Raleigh、North Carolina、美国、27612
- Carolina's GI Research
-
-
Ohio
-
Cleveland、Ohio、美国、44195
- Cleveland Clinic
-
Columbus、Ohio、美国、43215
- Remington Davis, Inc.
-
Mason、Ohio、美国、45040
- DelRicht Clinical Research - Cincinnati
-
Westlake、Ohio、美国、44145
- Northshore Gastroenterology Research, LLC
-
-
Oklahoma
-
Tulsa、Oklahoma、美国、74104
- Options Health Research
-
-
Oregon
-
Medford、Oregon、美国、97504
- Velocity Clinical Research
-
-
Pennsylvania
-
Harrisburg、Pennsylvania、美国、17110
- Susquehanna Research Group, LLC
-
-
Tennessee
-
Chattanooga、Tennessee、美国、37343
- Galen Medical Group - Downtown Gastroenterology Location
-
Chattanooga、Tennessee、美国、37421
- WR ClinSearch
-
Henderson、Tennessee、美国、37075
- DelRicht Clinical Research - Nashville
-
-
Texas
-
Arlington、Texas、美国、76012
- North Hills Medical Research Inc. (North Hills Familiy Medicine)
-
Dallas、Texas、美国、75230
- Zenos Clinical Research
-
El Paso、Texas、美国、10908
- Texas Gastro Research, LLC
-
Houston、Texas、美国、77030
- Houston Methodist Research Institute
-
Houston、Texas、美国、77099
- Pioneer Research Solutions Inc.
-
Houston、Texas、美国、77089
- Amir A Hassan, MD, PA
-
Houston、Texas、美国、77090
- Care and Cure Clinic
-
Lewisville、Texas、美国、75057
- Epic Clinical Research
-
Lubbock、Texas、美国、79905
- Texas Tech University Health Sciences Center
-
McAllen、Texas、美国、78503
- Biopharma Informatic, LLC
-
McKinney、Texas、美国、75070
- DelRicht Clinical Research - McKinney
-
San Antonio、Texas、美国、78229
- Gastroenterology Research of San Antonio
-
Spring、Texas、美国、77386
- A1 Clinical Network
-
-
Utah
-
Bountiful、Utah、美国、84010
- HP Clinical Research (Val R. Hansen)
-
West Jordan、Utah、美国、84065
- Velocity Clinical Research - Salt Lake City
-
-
Virginia
-
Manassas、Virginia、美国、20110
- Manassas Clinical Research Center
-
-
Wisconsin
-
Milwaukee、Wisconsin、美国、53215
- Wisconsin Center for Advanced Research
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Key Inclusion Criteria:
-
Is a male or female ≥18 years of age;
-
Has a diagnosis of Type 1 or Type 2 diabetes, according to the American Diabetes Association criteria;
-
Has a current diagnosis of diabetic gastroparesis defined by the following:
- Persistent gastrointestinal symptoms that in the opinion of the Investigator are consistent with gastroparesis within 6 months prior to Screening; AND
- Documented delayed gastric emptying as determined by gastric emptying breath test (GEBT), scintigraphy, or manometry.
-
Body mass index (BMI) between 18 and 49 kg/m2, inclusive;
-
Glycosylated hemoglobin (HbA1c) level <10% at Screening;
-
If receiving treatment with GLP-1RA, may be considered for the study if all of the following criteria are satisfied:
- The GLP-1 RA has been prescribed for the management of diabetes and not specifically for weight loss/weight management;
- Has been on a stable dose of GLP-1RA for a minimum of 3 months before Screening and is anticipated to sustain the same dose during GEBT and throughout the study;
- Is tolerating the GLP-1RA well based on Investigator's judgment;
- None of the study-qualifying signs/symptoms of gastroparesis are solely attributable to the use of GLP-1RA; and
- The symptoms of gastroparesis preceded the initiation of GLP-1RA therapy.
-
Willing to washout from ongoing treatment for gastroparesis.
Key Exclusion Criteria:
- Has known cause of gastroparesis other than diabetes (eg, idiopathic gastroparesis and/or gastroparesis attributed to surgery, viral illness, cancer, scleroderma, or other neurologic disorder);
- Has been hospitalized within 3 months prior to Visit 1 for diabetic gastroparesis and/or diabetic ketoacidosis and/or malnutrition;
- History or evidence of clinically significant arrhythmia;
- History of pyloroplasty, pyloromyotomy, or gastric peroral endoscopic myotomy, fundoplication, gastrectomy, vagotomy, or bariatric surgery;
- Currently receiving parenteral feeding or presence of a nasogastric or other enteral tube for feeding or decompression;
- Pyloric injection of botulinum toxin within 6 months of Screening;
- Positive test for drugs of abuse;
- Has a known allergy to eggs or spirulina;
- Females who are pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:CIN-102: Dose 15mg or 10mg
CIN-102, Dose 15 mg or 10 mg, twice daily for 12 weeks |
2 capsules twice daily for 12 weeks |
|
安慰剂比较:Placebo
Placebo for CIN-102, twice daily for 12 weeks |
2 capsules twice daily for 12 weeks |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Effect of CIN-102 to significantly decrease gastroparesis-related symptoms as compared to baseline based on the composite of the average ANMS GCSI-DD Nausea Sub-Scale and Vomiting Scores
大体时间:Over the last 2 weeks of the 12-week Treatment Period as compared to baseline
|
The American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary (ANMS GCSI-DD) Nausea Subscale scores and the Vomiting subscale scores will be averaged into a single value that ranges 0-4 (0 for no symptom and 4 for very severe) |
Over the last 2 weeks of the 12-week Treatment Period as compared to baseline
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
临床显着变化的发生率,根据研究者的意见,实验室参数、身体检查结果、12 导联 ECG 参数、体重测量。
大体时间:在 12 周的治疗期间
|
在 12 周的治疗期间
|
|
|
治疗中出现的不良事件 (TEAE) 的发生率
大体时间:在 12 周的治疗期间
|
在 12 周的治疗期间
|
|
|
治疗紧急严重不良事件 (SAE) 的发生率
大体时间:在 12 周的治疗期间
|
在 12 周的治疗期间
|
|
|
导致研究药物过早停药的 TEAE 发生率
大体时间:在 12 周的治疗期间
|
在 12 周的治疗期间
|
|
|
治疗紧急标记的实验室异常的发生率。
大体时间:在 12 周的治疗期间
|
在 12 周的治疗期间
|
|
|
在 12 周治疗期的最后 2 周评估的所有终点也将在 12 周治疗期的最后 6 周评估。
大体时间:在 12 周治疗期的最后 6 周内
|
在 12 周治疗期的最后 6 周内
|
|
|
每剂 CIN-102 的 PGIS 变化
大体时间:从基线到第 12 周
|
从基线到第 12 周
|
|
|
每剂量 CIN-102 的 PGIC 变化
大体时间:从基线到第 12 周
|
从基线到第 12 周
|
|
|
ANMS GCSI-DD 恶心量表和呕吐评分较基线平均降低 ≥0.5 的应答者百分比
大体时间:12 周治疗期的最后 2 周
|
12 周治疗期的最后 2 周
|
|
|
平均 ANMS GCSI-DD 恶心量表和呕吐评分综合得分较基线降低 ≥30% 的受试者百分比
大体时间:12 周治疗期的最后 2 周
|
12 周治疗期的最后 2 周
|
|
|
12 周治疗期内 ANMS GCSI-DD 恶心量表和呕吐评分与患者严重程度总体印象 (PGIS) 和患者总体印象变化 (PGIC) 之间的关系;
大体时间:12周的治疗期间
|
12周的治疗期间
|
|
|
接受胰高血糖素样肽 1 受体激动剂 (GLP-1RA) 的受试者中平均 ANMS GCSI-DD 恶心量表和呕吐评分的综合变化
大体时间:在 12 周的治疗期内与基线相比
|
在 12 周的治疗期内与基线相比
|
|
|
接受 GLP-1RA 治疗的受试者中,ANMS GCSI-DD 恶心量表和呕吐评分较基线平均降低 ≥0.5 的应答者百分比
大体时间:12 周治疗期的最后 2 周
|
12 周治疗期的最后 2 周
|
|
|
接受 GLP-1RA 的受试者在 ANMS GCSI-DD 恶心量表和呕吐评分上较基线降低 ≥30% 的百分比
大体时间:12 周治疗期的最后 2 周
|
12 周治疗期的最后 2 周
|
|
|
接受 GLP-1RA 治疗的受试者中 ANMS GSCI-DD 总分和胃轻瘫相关症状综合的变化;
大体时间:与基线相比,在 12 周治疗期的最后 2 周内
|
与基线相比,在 12 周治疗期的最后 2 周内
|
|
|
The percentage of symptom-free days in the ANMS GCSI-DD Total Score, a composite of the Nausea Sub-Scale and Vomiting Scores, and Sub-Scale Scores
大体时间:Over the last 2 weeks of the 12-week Treatment Period
|
Symptomatic days defined as >mild (ANMS GCSI-DD scores >2) |
Over the last 2 weeks of the 12-week Treatment Period
|
|
Percentage of subjects with a history of a lack of response or who could not tolerate metoclopramide therapy or other prokinetics, who demonstrate a >30% reduction from baseline on a composite score
大体时间:Over the last 2 weeks of the 12-week Treatment Period as compared to baseline
|
Composite of the average ANMS GCSI-DD Nausea Sub-Scale and Vomiting Scores |
Over the last 2 weeks of the 12-week Treatment Period as compared to baseline
|
|
Effect of CIN-102 to significantly decrease the severity of gastroparesis-related symptoms as compared to baseline
大体时间:Over the last 2 weeks of the 12-week Treatment Period as compared to baseline
|
Based on the average ANMS GCSI-DD Total and Sub-Scale Scores |
Over the last 2 weeks of the 12-week Treatment Period as compared to baseline
|
合作者和调查者
出版物和有用的链接
有用的网址
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.